IE83882B1 - 1-[N-Alkyl-N-(halo-3'-pyridylmethyl)amino]- 1-mono/dialkylamino-2-nitroethylene derivatives for use against fleas on pets - Google Patents
1-[N-Alkyl-N-(halo-3'-pyridylmethyl)amino]- 1-mono/dialkylamino-2-nitroethylene derivatives for use against fleas on pets Download PDFInfo
- Publication number
- IE83882B1 IE83882B1 IE1993/0390A IE930390A IE83882B1 IE 83882 B1 IE83882 B1 IE 83882B1 IE 1993/0390 A IE1993/0390 A IE 1993/0390A IE 930390 A IE930390 A IE 930390A IE 83882 B1 IE83882 B1 IE 83882B1
- Authority
- IE
- Ireland
- Prior art keywords
- formula
- active ingredient
- hydrogen
- fleas
- compound
- Prior art date
Links
- 241000258242 Siphonaptera Species 0.000 title claims description 87
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 91
- 239000004480 active ingredient Substances 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 241000282326 Felis catus Species 0.000 claims description 27
- 210000004369 Blood Anatomy 0.000 claims description 23
- 230000001058 adult Effects 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 241000282472 Canis lupus familiaris Species 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 17
- 239000000460 chlorine Substances 0.000 claims description 16
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 14
- 206010061217 Infestation Diseases 0.000 claims description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 11
- 239000011630 iodine Substances 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 230000000366 juvenile Effects 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000007910 systemic administration Methods 0.000 claims description 6
- 230000001276 controlling effect Effects 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 230000000974 larvacidal Effects 0.000 claims description 2
- 230000003151 ovacidal Effects 0.000 claims description 2
- 231100000194 ovacidal Toxicity 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 18
- 235000013601 eggs Nutrition 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000003826 tablet Substances 0.000 description 10
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- 239000000454 talc Substances 0.000 description 9
- 235000012222 talc Nutrition 0.000 description 9
- 229910052623 talc Inorganic materials 0.000 description 9
- 241000258924 Ctenocephalides felis Species 0.000 description 8
- 210000003608 Feces Anatomy 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 229940014259 Gelatin Drugs 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 230000000240 adjuvant Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- -1 etc. Chemical group 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000490513 Ctenocephalides canis Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000002903 organophosphorus compounds Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000006004 Flea Infestations Diseases 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000382353 Pupa Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940100445 WHEAT STARCH Drugs 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000000249 desinfective Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000749 insecticidal Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 210000001520 Comb Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229960002900 Methylcellulose Drugs 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 229940093429 Polyethylene Glycol 6000 Drugs 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N Solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000000895 acaricidal Effects 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 150000008047 benzoylureas Chemical class 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000004495 emulsifiable concentrate Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002949 juvenile hormone Substances 0.000 description 1
- 150000003633 juvenile hormone derivatives Chemical class 0.000 description 1
- 229930014550 juvenile hormones Natural products 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002393 scratching Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Description
Patents Act, 1992
930390
-[N-ALKYL-N-(HALO-3’-PYRIDYLMETHYL)AMlNO]
MONO/DIALKYLAMINONITROETHYLENE DERIVATIVES FOR USE
AGAINST FLEAS ON PETS
NOVARTIS AG
-{N-Alkvl-N-(halo-3’-pvridvlmethyl)aminolmono/dialkvlaminonitroethvlene
derivatives for use against fleas on pets
The present invention relates to 1-[N—all
mono/dialkylaminonitroethylene derivatives of the following formula I for use in
a method of controlling fleas in domestic animals, especially in dogs and cats,
wherein systemic administration is preferred. The invention relates also to a
method of inhibiting the infestation of dogs and cats by fleas which comprises the
systemic administration of the said compound, in an amount effective against
fleas, to the said domestic animal, for example the dog or the cat, by way of the
digestive tract or the blood of the host animal.
The 1-[N-alkyl-N-(halo-3’—pyridy|methyl)amino]mono/dialkylaminonitro-
ethylene derivatives mentioned in the introduction have the following chemical
structure of formula I:
wherein
Hal is halogen, such as fluorine, chlorine, bromine or iodine;
Fl, is hydrogen, C1-Cealkyl or C3-Cycycloalkyl;
R2 is hydrogen, C,-Csalkyl or C3-Cycycloalkyl, and
R3 is hydrogen or C,-Csalkyl.
lt is a matter of course that the cis/trans isomers are embodiments of the present
invention. Said isomers can exhibit different activities.
Owing to their pronounced activity against fleas, preference is given within the
scope of formula I to the following subgroups:
Group a: Compounds of formula I wherein Hal is in the 6-position. Special
preference is given to such compounds wherein Hal is fluorine, chlorine or
bromine, especially chlorine.
Group b: Compounds of formula I wherein R, is hydrogen, C,-Cgalkyl or C3-
Cecycloalkyl, preferably hydrogen, methyl or ethyl or cyclopropyl, especially ethyl.
Group c: Compounds of formula I wherein R2 is C1-Caalkyl or cyclopropyl,
especially methyl.
Group d: Compounds of formula I wherein Hal is halogen, such as fluorine,
chlorine, bromine or iodine; R, is hydrogen, methyl, C3-Cealkyl or C3-Cycycloalkyl
and R2 is hydrogen or C1-Cealkyl.
Group e: Compounds of the formula I wherein Hal is 6’-chlorine, R1 is hydrogen,
methyl or ethyl, and R2 is hydrogen or methyl.
Within groups (a) to (e) preference is given above all to those compounds
wherein R3 is hydrogen.
Owing to its pronounced systemic activity against fleas, special preference is
given to the following compound:
1-[N-ethyl—N—(6’-chloro-3’-pyridylmethyl)amino]methylaminonitroethylene,
and also to its immediate homologues. Immediate homologues embrace all
compounds of groups (a) to (e) wherein Hal is fixed in the 6’-position.
Within the scope of the present invention, depending on the number of carbon
atoms indicated, the term "alkyl" is to be understood as meaning, for example, the
following straight-chained and branched groups: methyl, ethyl, n-propyl, isopropyl,
n-butyl, sec-butyl, tert-butyl, isobutyl, etc.. Here and hereinafter, Hal is to be
understood as being fluorine, chlorine, bromine or iodine, preferably fluorine,
chlorine or bromine, but especially chlorine. Depending on the number of carbon
I\.)
Uw
atoms indicated, cycloalkyl by itself or as part of a substituent is cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, etc., cyclopropyl being especially preferred.
Compounds of the structural type falling within the scope of formula I, including
processes for their preparation, are described in EP—O 302 389. The compounds
of formulal can be prepared in accordance with the methods disclosed in EP—O
302 389 or analogously to the compounds described therein. That publication
discloses a broad class of compounds of which the above representatives
constitute only a selected subgroup, although they do not appear therein as a
group. The class of compounds disclosed in EP-0302 389 is described as
insecticidal and acaricidal. Plant-destructive insects and mites are given as the
preferred area of application. There is no reference to activity against fleas.
EP—O 302 833 likewise discloses a group of compounds which are structurally
similar to those of the above formula l or which to some extent overlap structurally
therewith. The essential structural difference between the compounds
specifically disclosed and those of formula l is that the former have an
unsubstituted pyridyl group, whereas the compounds of formula l are mono--
halogenated at the pyridyl radical. The compounds disclosed in EP—O 302 833
are said to be valuable active ingredients in pest control, while being well
tolerated by warm-blooded animals and plants, and to be suitable for controlling
pests in and on animals and plants. Among the animal—injurious insects, specific
reference is made to the order Siphonaptera (fleas).
In EP—O 255 803 the three ovicidal and larvicidal classes of active compounds
juvenile hormones, benzoylureas and triazine derivatives are disclosed
exclusively.
It has now been found, surprisingly, that in the case of the compounds of the
above formula I, the introduction of a halogen atom into the pyridyl radical brings
about quite unexpected and significantly increased activity against fleas. That is
very clear from a comparison of a typical basic representative according to the
present formula I and the structurally closest typical basic representative from the
prior art. The relevant
I\)
L/I
comparison data are given below in the Biological Examples.
The outstanding activity against fleas exhibited by the compounds of formula l is
of such significance because the infestation by fleas of domestic animals and
pets, especially of dogs and cats, is a problem for vets and animal owners alike to
which there is still no adequate solution.
Owing to the complicated life cycle of the flea, none of the known methods of
controlling these extremely troublesome parasites, which not only transmit
diseases but are also the cause of unpleasant allergies, is totally satisfactory,
especially since most of the known methods of control are based on the
application of the active compound to the habitat of the various flea stages. As a
result of the complex life cycle of the flea, however, that procedure is very
laborious and cannot, in practice, cover all of the habitats, and is accordingly
unreliable.
For example, control aimed at treating the adult flees in the fur, which is generally
effected by applying an anti-flea composition to the fur of the host animal, takes
no account at all of the various juvenile stages of the fleas, which live not only in
the fur of the animal, but also mainly on the floor, on carpets, on the animal’s
sleeping place, on chairs, in the garden and in all the other places with which the
infested animal comes into contact. Adult cat and dog fleas (ctenocephalides
felis and C. canis) normally live in the fur of the host cat or host dog. They live on
the blood of the host animal and lay their eggs in its fur. Since those eggs are
not self-adhering, however, they generally soon fall off and can be found on the
floor, on carpets, in the dog’s or cat’s basket, on the chairs used by the animal, in
the garden, in the yard, etc..
That means that the whole of the pets’ living area is contaminated with flea eggs,
from which the larvae develop within two days. The larvae have three distinct
stages of development, each of which lasts three days. In the final stage the
larva spins its cocoon and becomes a pupa. Under favourable conditions, i.e. at
33°C and a relative humidity of 65 %, the metamorphosis from egg to pupa takes
place in about 8 to 10 days. After about another 8 days the young, fully-formed
fleas develop in the cocoons that are still lying on the floor, the carpets, the
sleeping places, the chairs, etc.. The young adult fleas remain there until they
sense the presence of an acceptable host animal, then they hatch from their
cocoons and attempt to jump onto the host animal. Thus it takes at least three
weeks for an egg to develop into a young adult flea that is capable of reinfesting
the host animal.
The young flea may, however, remain in its cocoon for months, possibly for up to
a year. On the other hand, under less favourable conditions the development
from egg to young adult flea may take from 4 to 5 months. To reach sexual
maturity, fleas require blood as food in order to be able to reproduce, and that
blood must be from the appropriate host animal. It is normally obtained from the
excreta of the adult fleas living on the host animal. Those excreta contain large
amounts of undigested blood.
That long life cycle, which proceeds separately from the host animal, has a
significant influence on the successful control of fleas on the host animal.
Only when the fleas in the fur of the host animal can be successfully controlled
very quickly, i.e. when all the adult fleas are killed within a very short time with a
suitable active ingredient, is the cat or the dog protected against the risk of
reinfestation by newly hatched young fleas from its living space.
Flea infestation of dogs and cats has unpleasant consequences not only for the
animal to be treated but also for the animal’s owner. Such drawbacks lead, for
example, to local irritation or troublesome itching and often result in intense
scratching. A large number of the animals become allergic to the excreta of the
fleas, which leads to very itchy and crusty skin changes around the sites of the
bites on the animal’s body. Those skin changes normally have a diameter of
approximately 3 mm or more and often make the animal prone to biting and
cause it to scratch, leading to loss of fur in places.
Furthermore, flea-infested animals are constantly exposed to the risk of
infestation by dipylidium, a species of tape worm, which is transmitted by fleas.
Flea infestation is not only extremely troublesome for the affected animal, but
also has unpleasant consequences for the animal’s owner, since it will eventually
become evident to him from the unusual behaviour of his pet that it is ill and
suffering and that he must help it. What is more, it can become unpleasant for
the animal’s owner if he gives up keeping his infested animal, or if it dies or is
removed temporarily from its usual environment, since in the event of the
prolonged absence of a suitable host animal, the newly hatched fleas on the floor
will be forced to infest the human, although they are unable to live on human
blood as their only source of food. Even when the dog or the cat is present, the
animal’s owner can still be bitten by the fleas.
In addition, dog and cat fleas, or their excreta, can lead to allergy-like skin
disorders in some people, which in many cases means that the pet must be given
up. The desire for effective control of fleas in dogs and cats has therefore
existed for centuries.
A number of conventional methods of control are known, but they have various
disadvantages. If, for example, flea combs surface-coated with an insecticide are
used, the animal’s owner has no alternative but to comb the animal intensively
and often which, depending on the size of the animal, may take from a few
minutes to an hour and will not be accepted patiently by every animal. However,
not every animal owner is prepared to devote the time to this. The use of
corresponding anti—flea shampoos is often unsuccessful, since most cats, and
also many dogs, can be bathed, if at all, only by force, with the result that water
and active ingredient are spilt and have to be cleared up. In addition, the effect
of such a bath treatment lasts about a week at most, and the laborious procedure
has to be repeated. The same or very similar problems can be expected with the
use of dips or rinses. The use of dusting powders is generally also not accepted
by the animal without resistance, since it takes several minutes to treat the whole
surface of the fur uniformly, and some of the dust will inevitably get into the
mouth, nose and eyes of the animal. Even with careful application, it cannot be
ensured that the animal and the human will not inhale any powder. It is virtually
inevitable that the human will also come into contact with the composition to a
greater OF lesser extent.
When using sprays, many people may be unpleasantly surprised to find that
most animals, especially cats, run away or react aggressively at the mere sound
of the spray. In addition, sprays also have all the disadvantages listed for dusting
powders, added to which they become even more finely dispersed in the
atmosphere and are therefore inhaled by human and animal. Fleas are
frequently controlled by means of so-called flea collars, which ensure good
effectiveness temporarily. This treatment has a certain weakness, owing
especially to its locally very limited area of application. Although the killing action
in the region of the neck and chest is generally 100 °/o, more remote parts of the
body are scarcely affected. in addition, those collars are active for a limited time.
Furthermore, many of the collars are unattractive and may annoy the animal. It is
also possible nowadays to buy medallions, which can be hung from conventional
collars and are supposed to be effective. Although they are attractive in
appearance, the action of those medallions is unsatisfactory, since they have
inadequate contact with the fur. Some anti-flea organophosphorus compounds
are also available as spot-on formulations and are thus applied to a locally limited
area of the fur. They generally have good short-term activity against adult fleas,
but the compositions used often have toxic properties that present problems.
Some organophosphorus compounds have also been administered orally, but
they are subject to strict safety restrictions and must on no account be
administered simultaneously with other organophosphorus compounds.
Overall it may be said that the conventional methods, which seek to kill the adult
flea, produce such unsatisfactory results chiefly because they depend on the
patience and the skill of the user when handling the infested host animal. The
success of the current compositions stands and falls with the frequency and
thoroughness with which the user, normally the animal’s owner, applies the active
ingredient to the host animal and the thoroughness with which he disinfects the
environment in which the host animal lives. The conventional methods are
relatively expensive, time-consuming and not especially successful in the long
term. In the short term, relief can certainly be obtained with the conventional
compositions.
What has hitherto not been adequately taken into account in the case of the
conventional methods and compositions is the fact that, owing to the particular
life cycle of the flea, dogs and cats are repeatedly reinfested by new fleas, partly
because contact with the flea eggs, flea larvae and young adult fleas on the floor
and/or in the immediate vicinity of the animal is unavoidable, and partly because
many pet animals constantly come into contact with infested members of their
own species.
Constantly recurring reinfestation is inadequately prevented by conventional
compositions or can be prevented only by the application of large amounts of
disinfectant, etc..
It has now been found, surprisingly, that using certain systemic methods of
administration and using compounds of formula l as active ingredients, it is
possible to eliminate the adult fleas very rapidly and completely and thus to
inten/ene in the complex development cycle of the flea by blocking that cycle.
Since those compounds exhibit all of their outstanding anti-flea activity also when
they are administered to the host animal systemically, i.e. orally, parenterally,
subcutaneously, intramuscularly or intravenously, it is possible, by means of their
specific periodic administration, in a simple manner to break the vicious circle of
constantly recurring reinfestation described above until all the juvenile stages in
the living area of the host animal have died. The fleas are killed and prevented
from reproducing, the juvenile stages are prevented from maturing and are no
longer able to infest the host animal, so that the living area of dogs and cats can
be kept free of fleas for a prolonged period. The only unavoidable source of
reinfestation is contact with infested members of the same species and that
aspect can of course be excluded one hundred percent only by means of long-
term treatment. That residual risk is, however, of minor importance.
It has now been found that by oral administration of compounds of formula I in an
amount effective against fleas, it is possible for infestation by fleas of domestic
animals, such as cats and dogs, to be drastically reduced or completely
prevented.
What is astonishing in connection with the present invention, however, is that full
activity can be achieved even when an active ingredient is administered to the
host animal in relatively low concentrations and reaches its target of the adult flea
only by the circuitous route via the gastro-intestinal tract and thus via the blood
sucked up by the flea. Since systemic administration of the active ingredient
bringsabout the total mortality of the adult fleas, it is now possible to eradicate
the fleas. A combination of this systemic administration of the active ingredient
with accompanying measures, for example disinfection of the living area of the
host animal, makes it possible to eliminate the flea problem even more rapidly,
but even without those accompanying measures the flea population is reduced
completely or to an acceptable minimum within a few weeks or at the most
months.
The compounds of formula I exhibit activity against juvenile flea stages insofar as
flea larvae that hatch from the flea eggs are substantially dependent on the
excreta of the adult fleas, since they live on that excrement. However, flea
excreta comprise large amounts of undigested blood from the host animal and
serve as a source of protein for the developing fleas. Since, however, the
compounds of formula I kill the adult fleas very rapidly, the necessary excreta are
not available and the juvenile stages are deprived of their nutrient base and
therefore die before they reach the adult stage. This is also a decisive
contributing factor in the interruption of the complex life cycle of the flea and
prevents the host animals from being constantly reinfected in their preferred living
area by the eggs, and the larvae hatching therefrom, that are scattered all over it.
The present invention thus has two objects, on the one hand the afore-described
method of preventing the reinfestation of domestic animals by fleas, and
simultaneously of course the inhibition of the reproduction of fleas.
it is essential to the invention that the compounds of formula I are administered in
such a manner that they can be taken up in sufficient amounts by the adult,
sucking flea with the blood of the host animal and kill the adult flea rapidly before
it can provide sufficient uncontaminated food for the flea larvae by way of its
excreta. This is achieved with the compounds of the invention using various
forms of administration, for example by administering the formulated active
ingredient orally. "Formulated" in this case means, for example, in the form of a
powder, a tablet, granules, a capsule, an emulsion or a foam, in
microencapsulated form, etc.; the animal need not necessarily be given the
composition directly, rather it is advantageously mixed with its food, since that
form of administration presents the fewest problems both to the host animal and
to the person administering the composition. In addition to customary formulation
ingredients, any composition that is to be administered orally may of course
comprise further adjuvants that encourage the host animal to take the
composition voluntarily, for example suitable odorants and flavourings. Oral
administration, being easy to carry out, is preferred according to the invention. A
further form of administration is parenteral administration, for example by
subcutaneous injection or intravenous injection, or with a long-term composition
(depot form) in the form of an implant.
Oral administration includes, for example, the administration of dog and cat food
ready mixed with the active ingredient, for example in the form of biscuits or
treats, chewable tablets, water-soluble capsules or tablets, in a water-soluble
form that can be added to the food in the form of drops or in other forms that can
be mixed with the animal food. The implants also include any means that can be
introduced into the body of the animal in order to release active ingredient.
By selection of a suitable formulation, it is possible to promote the ability of the
active ingredient to penetrate through the living tissue of the animal, and/or to
maintain its availability. That is important when, for example, a very sparingly
soluble active ingredient is used, the low solubility of which requires means for
enhancing solubility, since the animal’s body fluid is capable of dissolving only
small amounts of active ingredient at a time.
The administration of veterinary medicinal additives to animal food is well known
in the field of animal health. it is usual first to prepare a so-called premix in which
I\)
U1
the active ingredient is dispersed in a liquid or is in finely divided form in solid
carriers. That premix can normally comprise about 1 to 800 g of compound per
kg of premix, depending on the desired final concentration in the food.
It is also known that active ingredients may be hydrolysed or weakened by the
constituents of the food. Such active ingredients are routinely formulated in a
protective matrix, for example in gelatin, before being added to the premix.
The present invention therefore relates to the object of eliminating the adult fleas
on the domestic animal, as well as to preventing the further development of the
flea larvae by depriving them of food, which is equivalent to systemic prevention
of the reinfection of domestic animals, especially of domestic animals by fleas.
This is achieved by administering to the said host animal orally at least one
compound of formula I in an amount effective against fleas.
The present invention thus also relates to the object of preventing the
reproduction of fleas, which comprises making available to fleas as food, by
means of the systemic administration of the active ingredient to the host animal,
contaminated blood that comprises at least one compound of formula I in an
amount effective against fleas. This is most easily achieved by administering to
the host animal, in the form of a food additive, a compound of formula I in an
amount effective against fleas, and in that way allowing it to reach the fleas living
on the host animal.
The compounds of formula I are advantageously administered in a dose of from
0.01 to 800, preferably from 0.1 to 200, especially from 0.5 to 30, mg/kg of body
weight of the host animal, oral administration being preferred.
A good dose that can be administered to the host animal regularly is from 0.5 to
100mg/kg of body weight. Administration is advantageously effected daily or
weekly.
The total dose may vary for the same active ingredient from one species of
animal to another as well as within a species of animal, since it depends inter alia
on the weight and the constitution of the animal.
When used according to the invention, the active ingredient is not normally
administered in pure form, but preferably in the form of a composition which
comprises in addition to the active ingredient constituents that assist
administration, suitable constituents being those that are tolerated by the host
animal. It is of course possible, as well as controlling the adult fleas in
accordance with the invention, additionally to use conventional methods that
control the juvenile flea stages, although the latter is not absolutely essential.
Such compositions to be administered in accordance with the invention generally
comprise from 0.1 to 99% by weight, especially from 0.1 to 95 % by weight, of a
compound of formula I and from 99.9 to 1 °/o by weight, especially from 99.9 to 5
% by weight, of a solid or liquid, non-toxic adjuvant, including from O to 25 °/o by
weight, especially from 0.1 to 25 0/0 by weight, of a non-toxic surfactant.
Whereas commercial products will preferably be formulated as concentrates, the
end user will normally employ dilute formulations.
The compositions may also contain further auxiliaries such as stabilisers,
antifoams, viscosity regulators, binders, tackifiers as well as fertilisers or other
active ingredients for obtaining special effects.
The materials known from veterinary medicinal practice for oral means can be
used as formulation excipients. Some examples are given below.
Suitable excipients are especially fillers, such as sugars, for example lactose,
saccharose, mannitol or sorbitol, cellulose preparations and/or calcium
phosphates, for example tricalcium phosphate or calcium hydrogen phosphate,
and binders, such as starch pastes using, for example, corn, wheat, rice or potato
starch, gelatin, tragacanth, methylcellulose and/or, if desired, disintegrators, such
as the above—mentioned starches, also carboxymethyl starch, cross-linked
polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate.
Adjuvants are especially flow conditioners and lubricants, for example silicic acid,
talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or
polyethylene glycol. Dragée cores can be provided with suitable, optionally
enteric, coatings, there being used inter alia concentrated sugar solutions which
may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or
titanium dioxide, or coating solutions in suitable organic solvents or solvent
mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose
preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose
phthalate. Dyes, flavourings or pigments may be added to the tablets or dragée
coatings, for example for identification purposes or to indicate different doses of
active ingredient.
Other orally administrable compositions are dry-filled capsules comprising gelatin,
and also soft sealed capsules comprising gelatin and a plasticiser, such as
glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in
the form of granules, for example in admixture with fillers, such as lactose,
binders, such as starches, and/or glidants, such as talc or magnesium stearate,
and, if desired, stabilisers. in soft capsules, the active ingredient is preferably
dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid
polyethylene glycols, to which stabilisers may also have been added. Preference
is given inter alia to capsules that are easily bitten through or swallowed without
being chewed.
The compositions of the present invention can be prepared in a manner known
per se, for example by means of conventional mixing, granulating, confectioning,
dissolving or lyophilising processes. For example, pharmaceutical compositions
for oral administration can be obtained by combining the active ingredient with
solid carriers, optionally granulating a resulting mixture, and processing the
mixture or granules, if desired or necessary after the addition of suitable
excipients, to form tablets or dragée cores.
The following Examples illustrate the invention described above, but do not limit
its scope in any way. Temperatures are given in degrees Celsius.
Table: Examples of compounds of formula 1 that can be used in accordance with
the invention
NRQR3
/ \ N02 (D
Hal \ l [IQ] H
N
Comp. Hal R1 R3 R3 melting point
No. in°C
.1 6-Cl CH3 CH3 H 87-90
1.2 6-Cl C3H3 CH3 H yellow oil
1.3 6-Cl CH3 CZH3 H 112-114
1.4 6-Cl CH3 C3H7-i H 133-135
1.5 6-Cl CH3 C4-H3-n H
1.6 6-Cl CH3 C4-H3-t H
.7 6-Cl CH3 C4-H3—s H
1.8 6-Cl CH3 C5-H3-n H
1.9 6-Cl CH3 C3-H13-n H
1.10 6-F CH3 CH3 H 100-1005
1.11 5—Br CH3 CH3 H 116-117
.12 2-Cl CH3 CH3 H 106-113
1.13 6-Cl C3H7-iso CH3 H
1.14 6-Cl C4-H3-n CH3 H
1.15 6-Cl C4-H3-tert CH3 H
1.16 6-Cl C4-H3-sec CH3 H
1.17 6-Cl C3-H13-n CH3 H
.18 6-Cl cyclopropyl CH3 H 104-105
1.19 6-Cl cyclobutyl CH3 H
1.20 6-Cl cyclopentyl CH3 H
1.21 6-Cl cyclohexyl CH3 H
1.22 6-Cl cycloheptyl CH3 H
1.23 6-Cl H CH3 H 158-161
Comp. Hal R1 R3 R3 melting point
No. in °C
.24 6-Cl CQH5 H H 159-161
.25 6-Cl CH3 H H 202 decomp.
1.26 5-Cl CH3 CH3 H
.27 4-Cl CH3 CH3 H
.28 6-Cl cyclopropyl C3H5 H 144-146
1.29 6-F C3H5 CH3 H oil
.30 6-Br C3H5 CH3 H 79-80
.31 6-Cl H CH3 CH3 97-98
.32 6-Br CH3 CH3 H 130-131
.33 6-Cl CH3 CH3 CH3 110-112
1.34 6-Cl H CQH5 CH3 87-88
.35 6-Cl C3H7-iso H H resin
.36 6-Cl H H H 188-190
1.37 6-Cl C3H7-n H H 185-186
1.38 6-Cl C3H7-n H CH3 102-103
1.39 6-Cl C3H7—iso H CH3 119-120
1.40 6-Cl cyclopropyl H cyc|o- 113-115
propyl
In the Formulation Examples that follow, the term active ingredient stands for 1-
[N-ethyl-N-(6'-chloro-3’-pyridylmethy|)amino]methylaminonitroethylene
Example 1: Tablets comprising 25 mg of active ingredient can be prepared as
follows:
Constituents (for 1000 tablets)
active ingredient
lactose
.0 g
100.7 g
wheat starch 7.5 g
polyethylene glycol 6000 5.0 g
talcum 5.0 g
magnesium stearate 1.8 g
demineralised water q.s.
Pregaration: All the solid ingredients are first forced through a sieve having a
mesh size of 0.6 mm. Then the active ingredient, the lactose, the talcum and half
the starch are mixed together. The other half of the starch is suspended in 40 ml
of water and the suspension is added to a boiling solution of the polyethylene
glycol in 100 ml of water. The resulting starch paste is added to the main batch
and the mixture is granulated, if necessary with the addition of water. The
granules are dried overnight at 35°, forced through a sieve having a mesh size of
1.2 mm, mixed with the magnesium stearate and compressed to form tablets
having a diameter of about 6 mm which are concave on both sides.
Example 2: Tablets comprising 0.02 g of active ingredient are prepared as
follows:
Comgosition (for 10 000 tablets)
active ingredient 200.00 g
lactose 290.80 g
potato starch 274.70 g
stearic acid 10.00 g
talcum 200.00 g
magnesium stearate 2.50 g
colloidal silica 32.00 g
ethanol q.s.
A mixture of the active ingredient, the lactose and 194.70g of potato starch is
moistened with an ethanolic solution of the stearic acid and granulated through a
sieve. After drying, the remaining potato starch, the talcum, the magnesium
stearate and the colloidal silica are mixed in and the mixture is compressed to
l\)
U1
form tablets each weighing 0.1 g, which may, if desired, be provided with dividing
notches for finer adaptation of the dose.
Example 3: Capsules comprising 0.025 g of active ingredient can be prepared as
follows:
Composition (for 1000 capsules)
active ingredient 25.00 g
lactose 249.80 g
gelatin 2.00 g
corn starch 10.00 g
talcum 15.00 g
water q.s.
The active ingredient is mixed with the lactose, the mixture is moistened uniformly
with an aqueous solution of the gelatin and granulated through a sieve having a
mesh size of 1.2-1.5 mm. The granules are mixed with the dried corn starch and
the talcum and introduced in 300 mg portions into hard gelatin capsules (size 1).
Example 4: Premix (food additive)
0.25
4.75
part by weight of active ingredient and
parts by weight of secondary calcium phosphate, alumina, Aerosil,
carbonate or chalk are mixed until homogeneous with
95 parts by weight of an animal food.
Example 5: Premix (food additive)
0.40 part by weight of active ingredient and
.00 parts by weight of Aerosil/chalk (1:1) are mixed until homogeneous with
94.6 parts by weight of a commercial dry food.
Example 6: Emulsifiable concentrate
parts by weight of active ingredient are mixed with
parts by weight of the emulsifier, e.g. a mixture of alkylarylpolyglycol ether
with alkylarylpolysulfonates, and with
parts by weight of a solvent, until the solution has been completely
homogenised. Emulsions of the desired concentration are obtained by
dilution with water.
Example 7: Solutions (ed. for use as a drink additive)
percent by weight active ingredient in 2,2-dimethylhydroxymethyl-1,3-
dioxolane,
percent by weight active ingredient in diethylene glycol monoethyl ether,
percent by weight in polyethylene glycol 300, and
percent by weight in glycerol.
Example 8: Soluble powder
parts by weight of active ingredient
1 part by weight of sodium lauryl sulfate,
3 parts by weight of colloidal silica gel, and
71 parts by weight of urea.
The ingredients are mixed together and ground with one another until
homogeneous.
Other biologically active compounds or adjuvants that are neutral towards the
active ingredients and that have no adverse effect on the host animal to be
treated, as well as mineral salts or vitamins, can be added to the compositions
described.
Biological Examples
Example 9: Comparison test of action against Ctenocephalides felis (cat flea)
in accordance with the following protocol, both the active ingredient according to
the invention, 1-[N-ethyl-N-(6’-chloro-3’-pyridylmethyl)amino]methylamino—2-
nitroethylene having the chemical structure:
l\)
U1
NHCH3
Ji/N02
ffl
Cl \N H3C)
and the structurally most similar compound mentioned in EP-O 302 833, of the
formula:
NHCH3
\ NO2
/ I N
\
N H3C)
are tested for comparison purposes against an untreated control group of fleas.
Test protocol:
adult fleas of the species Ctenocephalides felis are introduced into a flat round
cage closed off at both ends with gauze. A vessel sealed at the bottom with a
parafilm membrane is then placed on the cage. The vessel contains blood
comprising 1.0 ppm of active ingredient and is heated to a constant temperature
of 37°C. The fleas take up the blood through the membrane. Evaluation is
effected 24 and 48 hours after the start of the test. The percentage reduction in
population (% activity) is determined from a comparison of the number of dead
fleas given treated blood with those given untreated blood (control group). 24
hours after treatment the blood is replaced with fresh blood that has likewise
been treated and the test is continued with the surviving fleas. The untreated
blood for the control group is also replaced after 24 hours.
_l3_efllt_g All three groups of fleas [(Control group/untreated blood); (Group A/-
blood treated with compound A of the invention) and (Group B/blood treated with
compound B from the prior art)] begin to take up blood as soon as they are
placed in the test apparatus. The behaviour of the control group and of Group B
(prior art) remains virtually unchanged over the duration of the test. in contrast,
only half an hour after the start of the test the first toxic signs appear in Group A
(treatment according to the invention). After 24 hours the following individual
results are observed using 2 x 20 fleas in each case (in % mortality):
Compound ppm a.i. Test 1 Test 2 Test 3 Test 4
B 1.0 0 °/o 5 % O % O %
A 1.0 100 % 95 % 95 °/o 100 °/3
Control 0.0 O % O °/o 0 0/0 0%
Example 10: In vivo comparison test of the action against Ctenocephalides felis
{cat flea)
In this comparative test, as in Example 9, compound A of the invention is again
tested on cats and compared with the structurally most similar compound B of the
prior art.
When other compounds from the Table are tested with the compounds of formula
I given by way of example, entirely comparable results are obtained.
Test protocol:
6 female domestic cats 1-2 years old and having a body weight of from 3.0 to 4.0
kg are divided into three groups of two animals. One group is already infested
with fleas, but remains untreated and serves as control group. One of the other
groups receives test compound A and the other receives test compound B, in
each case in a dose of 10 mg/kg of body weight, by means of a gelatin capsule
directly into the back of the throat. Each of the test compounds has been mixed
beforehand with lactose 1:1. Immediately after administration of the test
compounds the cats are infested with 20 fleas each (16 female and 4 male fleas)
in the region of the ridge between the shoulderbones. Further infestation with a
further 20 fleas is effected in the case of compound A on days +2, +4 and +6. In
the case of the cats treated with compound B and in the case of the comparison
group, further infestation with fleas is unnecessary, since all the fleas from the
initial infestation have survived._
The flea eggs are collected daily and counted. The number of dead fleas found
is also determined daily. The results for the 2 treated groups are compared both
with each other and with those for the control group.
Results: The number of dead fleas found and the egg production are shown in
the following Tables 1 and 2:
Table 1: Number of fleas killed
Compound Catno. dead fleas on day...
0 +1 +2 +3 +4 +5 +6 +7 +8 +9
*10*115*O 2*0 O O
A
343 9*10*82*O2*OOO
351 O*1000O00OO
B
266 O*OOOOOOOOO
70 3390*0OOO0OOO0
Control
599 O*OOOOO0OOO
* infestation with 20 fleas
In the case of compound A, only 6 hours after infestation with the first 20 fleas
there is 60% mortality. Even on the second day after fresh infestation with a
further 20 fleas, a further 55 °/; of the fleas are killed. Not until day 6 does the
activity of compound A fall to approximately 10 %. In contrast, no significant
difference is found between the control group and the group of cats treated with
to
(Jr
.22.
compound B. Compound B proves ineffective and unusable for oral
administration against fleas at the low test concentrations.
Table 2: Egg production
Compound Cat no. egg production on day...
+2 +3 +4 +5 +6 +7 +8 +9
V 325 0* 0 0* 0 37* 233 250 370
A
343 0* 0 0* 60 0* 186 240 283
351 240 306 403 423 350 333 343 290
B
266 106 266 386 313 286 290 326 303
339 60 133 186 300 310 313 290 233
Control
599 96110156146166 116 200170
* Infestation with 20 fleas
In the group treated with compound A, no flea eggs are found after the first and
second infestations with fleas. In the group of cats treated with compound B and
in the control group, the female fleas produce the usual number of eggs; no
significant differences are found.
The comparison test shows that compound A has good systemic activity against
adult fleas for a period of about 3-4 days. Compound B, on the other hand, can
be classed as completely ineffective at the test dose. It could be neither
predicted nor expected that the simple introduction of halogene into the pyridyl
group would bring about such a significant increase in activity as regards the
systemic action against fleas.
l\)
U1
The compounds for which physical data are given in the Table of compounds that
may be used in accordance with the invention exhibit activity against fleas that is
comparable with that of compound A of the invention. Especially striking is the
outstanding activity of compounds 1.1 to 1.4, 1.10 to 1.12, 1.18, 1.28, 1.29 and
136to1AO.
Claims (21)
1. Use of a compound of formula NRZR3 (I). l NO 2 wherein Hal is halogen, such as fluorine, chlorine, bromine or iodine; R1 is hydrogen, C.—C5-alkyl or C3—C7cycloalkyl; R2 is hydrogen, C,—C5a|kyl or C3-C7cycloalkyl, and R3 is hydrogen or C,-Csalkyl, in the preparation of a composition for the systemic control of adult fleas on domestic animals.
2. Use of a compound according to claim 1 of formula I wherein the active ingredient is a compound of formula I wherein Hal is in the 6-position and is preferably fluorine, chlorine or bromine, but especially chlorine.
3. Use of a compound according to claim 1 of formula I wherein the active ingredient is a compound of formula I wherein R1 is hydrogen, C,-C3-alkyl or C3-Cscycloalkyl preferably hydrogen, methyl or cyclopropyl, especially methyl.
4. Use of a compound according to claim 1 of formula I wherein the active ingredient is a compound of formula I wherein R2 is C,—C3alkyl or cyclopropyl, especially methyl.
5. Use of a compound according to claim 1 of formula I wherein the active ingredient is a compound of formula I according to any one of claims 2 to 4 wherein R3 is hydrogen.
6. Use of a compound according to claim 1 of formula I, wherein the domestic animal is a dog or a cat.
7. Use of a compound according to claim 6 of formula I, which comprises, as an accompanying measure, controlling the juvenile flea stages using conventional larvicidal or ovicidal anti—flea compositions.
8. Use of a compound according to any one of claims I to 7 of formula I, which comprises administering orally in regular individual doses a composition comprising the active ingredient.
9. Use of a compound according to any one of claims 1 to 7 of formula 1, which comprises administering the active ingredient to the host animal in concentrations of from approximately 0.01 mg/kg of body weight to approximately 800 mg/kg of body weight.
10. Use of a compound according to claim 9 of formula I. which comprises administering the active ingredient to the host animal in concentrations of from approximately 0.1 mg/kg of body weight to approximately 200 mg/kg of body weight.
11. Use of a compound according to claim 10, which comprises administering the active ingredient to the host animal in concentrations of from approximately 0.5 mg/kg of body weight to approximately 30 mg/kg of body weight..
12. Use of a compound according to either claim 9 or claim 10 of formula I, which comprises administering the active ingredient to the cat or the dog orally. 10 to U: 26
13. Use of a compound according to any one of claims 1 to 7 of formula I, which comprises administering the active ingredient regularly to the cat or the dog in a dose of from 0.5 mg/kg of body weight to approximately 100 mg/kg of body weight.
14. Use of a compound of formula wherein Hal is halogen, such as fluorine, chlorine, bromine or iodine; R, is hydrogen, C,—C6alkyl or C3—C7cycloalkyl; R2 is hydrogen, C,-Cealkyl or C3-C7cycloalkyl and R3 is hydrogen or C.-Csalkyl in the preparation of a composition for systemic administration to the blood of domestic animals for preventing fleas from reproducing on the said domestic animal.
15. Use of a compound according to claim 14 of formula I, wherein the active ingredient is one of the compounds of formula I defined in claims 2 to 4.
16. Use of a compound according to claim 14 of formula I, which comprises administering an effective amount of the active ingredient to the host animal with its food and allowing the active ingredient to be taken up by the fleas on the host animal with the blood they suck up. (J1 1O
17. A systemically active composition for preventing the infestation of domestic animals, especially of dogs and cats by fleas, which comprises, in food, in an amount effective against fleas, a compound of formula I (l), wherein Hal is halogen, such as fluorine, chlorine, bromine or iodine; R1 is hydrogen, C,-Cealkyl or C3-C7cycloalkyl; R2 is hydrogen, C,—C5alkyl or C3-C7cycloalkyl and R3 is hydrogen or C,-Cealkyl, together with excipients that are physiologically tolerable for animals.
18. A composition according to claim 17 comprising dog or cat food.
19. A composition according to claim 17, wherein the active ingredient is a compound of formula l according to any one of claims 2 to 4.
20. Food additive for the systemic control of fleas in domestic animals, which comprises as active ingredient, in an amount effective against fleas, a compound of formula I wherein Hal is halogen, such as fluorine, chlorine, bromine or iodine; R1 is hydrogen, C,-Csalkyl or C3-C7cycloalkyl; U1 R2 is hydrogen, C,-Cealkyl or C3-C7cyc|oa|ky|, and R3 is hydrogen or C,-Caalkyl.
21. A pack containing individual doses of a compound of formula I NO 2 wherein Hal is halogen, such as fluorine, chlorine, bromine or iodine; R, is hydrogen, C,-Cealkyl or C3—C7cyc|oalkyl; R2 is hydrogen, C,-Csalkyl or C3-C7cyc|oalkyl and R3 is hydrogen or C.-Csalkyl, in formulated form for oral administration against fleas in domestic animals, wherein the active ingredient is present in individual ready-for-use doses of from 0.01 mg/kg of body weight to approximately 800 mg/kg of body weight. F. R. KELLY & CO., AGENTS FOR THE APPLICANTS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1992/001161 WO1993024002A1 (en) | 1992-05-23 | 1992-05-23 | 1-[n-(halo-3-pyridylmethyl)]-n-methylamino-1-alkylamino-2-nitroethylene derivatives for use against fleas on pets |
Publications (2)
Publication Number | Publication Date |
---|---|
IE930390A1 IE930390A1 (en) | 1993-12-01 |
IE83882B1 true IE83882B1 (en) | 2005-04-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4973589A (en) | Method of preventing the reinfestation of dogs and cats by fleas | |
US5750548A (en) | 1- N-(halo-3-pyridylmethyl)!-N-methylamino-1-alklamino-2-nitroethylene derivatives for controlling fleas in domestic animals | |
RU2233590C2 (en) | Veterinary combination and method for flea control | |
CA2113908C (en) | 1-[n-(halo-3-pyridylmethyl)]-n-methylamino-1-alkylamino-2- nitroethylene derivatives for controlling fleas in domestic animals | |
US5416102A (en) | Method of preventing the reinfestation of dogs and cats by fleas | |
IL128093A (en) | Process and composition for the antiparasitic treatment of the surroundings of animals infested by darkling beetles | |
JP2012031171A (en) | Method for control of insect pest | |
IE83882B1 (en) | 1-[N-Alkyl-N-(halo-3'-pyridylmethyl)amino]- 1-mono/dialkylamino-2-nitroethylene derivatives for use against fleas on pets | |
AU725118B2 (en) | Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites | |
US20020040027A1 (en) | Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites | |
EP0027624B1 (en) | Composition for the control of cannibalism of pigs | |
US4389402A (en) | Method for the control of cattle grubs using pentadienone hydrazones | |
MXPA01003490A (en) | Oral combination of lufenuron and nitenpyram against fleas | |
MXPA99000799A (en) | Process and composition for the antiparasitic treatment of the anima's environment |